Details
Stereochemistry | |
Molecular Formula | C32H30F2N4O4 |
Molecular Weight | 572.6018 |
Optical Activity | UNSPECIFIED |
Additional Stereochemistry | Yes |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
Stereo Comments | ATROPISOMERISM AT TWO SITES |
SHOW SMILES / InChI
SMILES
CN1C(=O)N(C(=O)C2=C1C(F)=CC=C2)C3=C(C)C(=CC=C3)C4=C5C6=C(C[C@H](CC6)C(C)(C)O)NC5=C(C=C4F)C(N)=O
InChI
InChIKey=ZRYMMWAJAFUANM-INIZCTEOSA-N
InChI=1S/C32H30F2N4O4/c1-15-17(7-6-10-24(15)38-30(40)19-8-5-9-21(33)28(19)37(4)31(38)41)25-22(34)14-20(29(35)39)27-26(25)18-12-11-16(32(2,3)42)13-23(18)36-27/h5-10,14,16,36,42H,11-13H2,1-4H3,(H2,35,39)/t16-/m0/s1
Molecular Formula | C32H30F2N4O4 |
Molecular Weight | 572.6018 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.03 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
36.9 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
185 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
311 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1081 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1878 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
56 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
281 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
75 mg 1 times / day steady-state, oral dose: 75 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
592 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1024 ng/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
350 mg 1 times / day steady-state, oral dose: 350 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
388 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1586 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3019 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11390 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
28063 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
539 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2471 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
75 mg 1 times / day steady-state, oral dose: 75 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5527 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10715 ng × h/mL CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
350 mg 1 times / day steady-state, oral dose: 350 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.87 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8.02 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.7 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.3 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.6 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.7 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
900 mg single, oral dose: 900 mg route of administration: Oral experiment type: SINGLE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.9 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.7 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
75 mg 1 times / day steady-state, oral dose: 75 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
11 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
200 mg 1 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.2 h CLINICAL TRIAL https://link.springer.com/article/10.1007/s00228-017-2226-2 |
350 mg 1 times / day steady-state, oral dose: 350 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
BMS-986142 plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:59:20 GMT 2025
by
admin
on
Mon Mar 31 21:59:20 GMT 2025
|
Record UNII |
PJX9GH268R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
86582336
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
100000178344
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
DB15291
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
1643368-58-4
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
SUB194072
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY | |||
|
PJX9GH268R
Created by
admin on Mon Mar 31 21:59:20 GMT 2025 , Edited by admin on Mon Mar 31 21:59:20 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
human whole
blood assay (hWB) measuring BCR stimulated CD69
expression on B cells
COMPETITIVE INHIBITOR
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
OFF-TARGET->INHIBITOR |
IC50
|
||
|
TARGET -> INHIBITOR |
RAMOS CELLS
COMPETITIVE INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |